Guidelines for treatment of acute heart failure (JCS 2011)

Circulation Journal

Volumn 77, Issue 8, 2013, Pages 2157-2201

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

6 (3 DIMETHYLAMINOPROPIONYL) FORSKOLIN; ACETYLSALICYLIC ACID; ADRENALIN; ALANINE AMINOTRANSFERASE; ALDOSTERONE ANTAGONIST; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ASPARTATE AMINOTRANSFERASE; ATRIAL NATRIURETIC FACTOR ALPHA; CATECHOLAMINE; CREATINE KINASE MB; DIGOXIN; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; FUROSEMIDE; GLYCERYL TRINITRATE; ISOSORBIDE DINITRATE; LOPRINONE; MILRINONE; MORPHINE; NICARDIPINE; NICORANDIL; NIFEDIPINE; NITROPRUSSIDE SODIUM; NORADRENALIN; SPIRONOLACTONE; TORASEMIDE; TROPONIN T; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN;

ACUTE HEART FAILURE; ACUTE HEART INFARCTION; ANEMIA; ARTICLE; ARTIFICIAL VENTILATION; BLOOD PRESSURE REGULATION; CARDIOGENIC SHOCK; CARDIOVASCULAR MAGNETIC RESONANCE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CONGESTIVE CARDIOMYOPATHY; CONTINUOUS INFUSION; DELIRIUM; DISEASE SEVERITY; DOPPLER ECHOCARDIOGRAPHY; DRUG DOSE INCREASE; EARLY DIAGNOSIS; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; HEART ATRIUM FIBRILLATION; HEART AUSCULTATION; HEART EJECTION FRACTION; HEART TAMPONADE; HUMAN; HYPERTENSION; ISCHEMIC CARDIOMYOPATHY; JAPAN; KIDNEY FAILURE; LIVER CONGESTION; LOW DRUG DOSE; LUNG CONGESTION; LUNG EDEMA; LUNG WEDGE PRESSURE; MEDICAL DEVICE COMPLICATION; META ANALYSIS (TOPIC); MORTALITY; MULTICENTER STUDY (TOPIC); MYOCARDITIS; PALLIATIVE THERAPY; PNEUMONIA; PRACTICE GUIDELINE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); THORAX RADIOGRAPHY; VALVULAR HEART DISEASE;

ACUTE DISEASE; HEART FAILURE; HUMANS;

EID: 84880811647     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-66-0068     Document Type: Article

References (135)

1. Okura Y, Ramadan MM, Ohno Y, Mitsuma W, Tanaka K, Ito M, et al. Impending epidemic: Future projection of heart failure in Japan to the year 2055. Circ J 2008; 72: 489-491.
2. Guidelines for the Diagnosis and Treatment of Cardiovascular Diseases (1998-1999 Joint Working Groups Report). Guidelines for Treatment of Severe Acute Heart Failure. Jpn Circ J 2000; 64 (Suppl IV): 1129-1165 (in Japanese).
3. Guidelines for the Diagnosis and Treatment of Cardiovascular Diseases (2004-2005 Joint Working Groups Report). Guidelines for Treatment of Acute Heart Failure (JCS 2006). http://www.j-circ.or.jp/guideline/pdf/JCS2006_maruyama_h.pdf (in Japanese).
4. Nieminen MS, Böhm M, Cowie MR, Drexler H, Filippatos GS, Jondeau G, et al; ESC Committee for Practice Guideline (CPG). Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: The Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26: 384-416.
5. The Criteria Committee of the New York Heart Association. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels, 9th ed. Boston: Little, Brown and Company, 1994; 253-256.
6. Killip T 3rd, Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol 1967; 20: 457-464.
7. Forrester JS, Diamond G, Chatterjee K, Swan HJ. Medical therapy of acute myocardial infarction by application of hemodynamic subsets (second of two parts). N Engl J Med 1976; 295: 1404-1413.
8. Nohria A, Tsang SW, Fang JC, Lewis EF, Jarcho JA, Mudge GH, et al. Clinical assessment identifes hemodynamic profles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol 2003; 41: 1797-1804.
9. Ministry of Health, Labour and Welfare. http://www.mhlw.go.jp/ english/
10. Kawashiro N, Kasanuki H, Ogawa H, Matsuda N, Hagiwara N; Heart Institute of Japan--Department of Cardiology (HIJC) Investigators. Clinical characteristics and outcome of hospitalized patients with congestive heart failure: Results of the HIJC-HF registry. Circ J 2008; 72: 2015-2020.
11. Sato N, Kajimoto K, Asai K, Mizuno M, Minami Y, Nagashima M, et al; ATTEND Investigators. Acute decompensated heart failure syndromes (ATTEND) registry: A prospective observational mul-ticenter cohort study: Rationale, design, and preliminary data. Am Heart J 2010; 159: 949 e1-955 e1
12. Hamaguchi S, Yokoshiki H, Kinugawa S, Tsuchihashi-Makaya M, Yokota T, Takeshita A, et al; Japanese Cardiac Registry of Heart Failure in Cardiology Investigators. Effects of atrial fbrillation on long-term outcomes in patients hospitalized for heart failure in Japan: A report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 2009; 73: 2084-2090.
13. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: The Framingham study. N Engl J Med 1971; 285: 1441-1446.
14. Jessup M, Brozena S. Heart failure. N Engl J Med 2003; 348: 2007-2018.
15. Felker GM, Pang PS, Adams KF, Cleland JG, Cotter G, Dickstein K, et al; International AHFS Working Group. Clinical trials of pharmacological therapies in acute heart failure syndromes: Lessons learned and directions forward. Circ Heart Fail 2010; 3: 314-325.
16. Gheorghiade M, Filippatos G, De Luca L, Burnett J. Congestion in acute heart failure syndromes: An essential target of evaluation and treatment. Am J Med 2006; 119(Suppl 1): S3-S10.
17. Allen LA, Hernandez AF, O'Connor CM, Felker GM. End points for clinical trials in acute heart failure syndromes. J Am Coll Cardiol 2009; 53: 2248-2258.
18. Peacock WF 4th, Fonarow GC, Emerman CL, Mills RM, Wynne J; ADHERE Scientifc Advisory Committee and Investigators; Adhere Study Group. Impact of early initiation of intravenous therapy for acute decompensated heart failure on outcomes in ADHERE. Cardiology 2007; 107: 44-51.
19. Mebazaa A, Gheorghiade M, Piña IL, Harjola VP, Hollenberg SM, Follath F, et al. Practical recommendations for prehospital and early in-hospital management of patients presenting with acute heart failure syndromes. Crit Care Med 2008; 36(Suppl): S129-S139.
20. Nohria A, Lewis E, Stevenson LW. Medical management of advanced heart failure. JAMA 2002; 287: 628-640.
21. Lubien E, DeMaria A, Krishnaswamy P, Clopton P, Koon J, Kazanegra R, et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: Comparison with Doppler velocity recordings. Circulation 2002; 105: 595-601.
22. Cotter G, Metra M, Milo-Cotter O, Dittrich HC, Gheorghiade M. Fluid overload in acute heart failure--re-distribution and other mechanisms beyond fuid accumulation. Eur J Heart Fail 2008; 10: 165-169.
23. Field JM, Hazinski MF, Sayre MR, Chameides L, Schexnayder SM, Hemphill R, et al. Part 1: Executive summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122(Suppl 3): S640-S656.
24. McAlister FA, Stewart S, Ferrua S, McMurray JJ. Multidisciplinary strategies for the management of heart failure patients at high risk for admission: A systematic review of randomized trials. J Am Coll Cardiol 2004; 44: 810-819.
25. Davidson PM, Cockburn J, Newton PJ, Webster JK, Betihavas V, Howes L, et al. Can a heart failure-specifc cardiac rehabilitation program decrease hospitalizations and improve outcomes in high-risk patients? Eur J Cardiovasc Prev Rehabil 2010; 17: 393-402.
26. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): Developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society. Circulation 2005; 112: e154-e235.
27. Ishii H, Ichimiya S, Kanashiro M, Amano T, Imai K, Murohara T, et al. Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment-elevation myocardial infarction. Circulation 2005; 112: 1284-1288.
28. Suwa M, Seino Y, Nomachi Y, Matsuki S, Funahashi K. Multi-center prospective investigation on effcacy and safety of carperitide for acute heart failure in the 'real world' of therapy. Circ J 2005; 69: 283-290.
29. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351: 543-551.
30. Seino Y, Momomura S Multi-center, double-blind study of intravenous milrinone for patients with acute heart failure in Japan. Japan Intravenous Milrinone Investigators Crit Care Med 1996; 24: 1490-1497.
31. Lowes BD, Tsvetkova T, Eichhorn EJ, Gilbert EM, Bristow MR. Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol. Int J Cardiol 2001; 81: 141-149.
32. Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, et al; Steering Committee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study. Effcacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): A randomized double-blind trial. Lancet 2002; 360: 196-202.
33. Moiseyev VS, Põder P, Andrejevs N, Ruda MY, Golikov AP, Lazebnik LB, et al; RUSSLAN Study Investigators. Safety and ef-fcacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 2002; 23: 1422-1432.
34. Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, et al; SURVIVE Investigators. Levosimendan vs dobu-tamine for patients with acute decompensated heart failure: The SURVIVE Randomized Trial. JAMA 2007; 297: 1883-1891. Heart Failure Society of America
35. Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, et al. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail 2010; 16: e1-e194.
36. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, et al; ESC Committee for Practice Guidelines (CPG). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29: 2388-2442.
37. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, et al; OPTIMIZE-HF Investigators and Coordinators. Infuence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: Findings from the OPTIMIZE-HF program. J Am Coll Cardiol 2008; 52: 190-199.
38. The Antiarrhythmic Drugs Guideline Committee. The Guidelines for the use of antiarrhythmic drugs: Commentary on the CD-ROM version of the Guidelines and concept of the Sicilian Gambit. Tokyo: Lifemedicom Co., ltd. 2000 (in Japanese).
39. Members of the Sicilian Gambit. Antiarrhythmic therapy: A pathophysiologic approach. New York: Futura Publishing Company, Inc; 1994.
40. Neumar RW, Otto CW, Link MS, Kronick SL, Shuster M, Callaway CW, et al. Part 8: Adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122(Suppl 3): S729-S767.
41. Berg RA, Hemphill R, Abella BS, Aufderheide TP, Cave DM, Hazinski MF, et al. Part 5: Adult basic life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122(Suppl 3): S685-S705.
42. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al; American College of Cardiology Foundation; American Heart Association. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009; 53: e1-e90.
43. Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK, et al; Canadian Cardiovascular Society; American Academy of Family Physicians; American College of Cardiology; American Heart Association. 2007 focused update of the ACC/ AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2008; 51: 210-247.
44. Soran O, Kennard ED, Kfoury AG, Kelsey SF; IEPR Investigators. Two-year clinical outcomes after enhanced external counterpulsation (EECP) therapy in patients with refractory angina pectoris and left ventricular dysfunction (report from the International EECP Patient Registry). Am J Cardiol 2006; 97: 17-20.
45. Rao V, Oz MC, Flannery MA, Catanese KA, Argenziano M, Naka Y. Revised screening scale to predict survival after insertion of a left ventricular assist device. J Thorac Cardiovasc Surg 2003; 125: 855-862.
46. Lietz K, Long JW, Kfoury AG, Slaughter MS, Silver MA, Milano CA, et al. Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: Implications for patient selection. Circulation 2007; 116: 497-505.
47. Levy WC, Mozaffarian D, Linker DT, Farrar DJ, Miller LW; REMATCH Investigators. Can the Seattle heart failure model be used to risk-stratify heart failure patients for potential left ventricular assist device therapy? J Heart Lung Transplant 2009; 28: 231-236.
48. Stevenson LW. Clinical use of inotropic therapy for heart failure: Looking backward or forward? Part I: Inotropic infusions during hospitalization. Circulation 2003; 108: 367-372.
49. Stevenson LW. Clinical use of inotropic therapy for heart failure: Looking backward or forward? Part II: Chronic inotropic therapy. Circulation 2003; 108: 492-497.
50. Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr, Faxon DP, Freed MD, et al; 2006 Writing Committee Members; American College of Cardiology/American Heart Association Task Force. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118: e523-e661.
51. Bonow RO, Carabello BA, Kanu C, de Leon AC Jr, Faxon DP, Freed MD, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Society of Cardiovascular Anesthesiologists; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing com mittee to revise the 1998 Guidelines for the Management of Pa tients With Valvular Heart Disease): Developed in collaboration with the Society of Cardiovascular Anesthesiologists: Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation 2006; 114: e84-e231.
52. Vahanian A, Baumgartner H, Bax J, Butchart E, Dion R, Filippatos G, et al; Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology; ESC Committee for Practice Guidelines. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 2007; 28: 230-268.
53. Stout KK, Verrier ED. Acute valvular regurgitation. Circulation 2009; 119: 3232-3241.
54. Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK, et al. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: Developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/ AHA 2004 Guidelines for the Management of Patients With STElevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation 2008; 117: 296-329.
55. Eagle KA, Guyton RA, Davidoff R, Edwards FH, Ewy GA, Gardner TJ, et al; American College of Cardiology; American Heart Association. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation 2004; 110: e340-e437.
56. Emerman CL. Treatment of the acute decompensation of heart failure: Effcacy and pharmacoeconomics of early initiation of therapy in the emergency department. Rev Cardiovasc Med 2003; 4: S13-S20.
57. Tang WH, Mullens W. Cardiorenal syndrome in decompensated heart failure. Heart 2010; 96: 255-260.
58. Peacock WF, Braunwald E, Abraham W, Albert N, Burnett J, Christenson R, et al. National Heart, Lung, and Blood Institute working group on emergency department management of acute heart failure: Research challenges and opportunities. J Am Coll Cardiol 2010; 56: 343-351.
59. Alexiou VG, Ierodiakonou V, Dimopoulos G, Falagas ME. Impact of patient position on the incidence of ventilator-associated pneumonia: A meta-analysis of randomized controlled trials. J Crit Care 2009; 24: 515-522.
60. Muscedere J, Dodek P, Keenan S, Fowler R, Cook D, Heyland D; VAP Guidelines Committee and the Canadian Critical Care Trials Group. Comprehensive evidence-based clinical practice guidelines for ventilator-associated pneumonia: Prevention. J Crit Care 2008; 23: 126-137.
61. The Japanese Society of Intensive Care Medicine. Committee for the assessing functional category of ICUs. 2010 Revision of the bundles to prevent ventilator-associated pneumonia (in Japanese).
62. Guidelines for the Diagnosis and Treatment of Cardiovascular Diseases (2008 Joint Working Groups Report). Guidelines for the Diagnosis, Treatment and Prevention of Pulmonary Thromboembo-lism and Deep Vein Thrombosis (JCS 2009). http://www.j-circ.or.jp/guideline/pdf/JCS2009_andod_h.pdf (in Japanese).
63. Baba A, Hirata G, Yokoyama F, Kenmoku K, Tsuchiya M, Kyo S, et al. Psychiatric problems of heart transplant candidates with left ventricular assist devices. J Artif Organs 2006; 9: 203-208.
64. Sessler CN, Gosnell MS, Grap MJ, Brophy GM, O'Neal PV, Keane KA, et al. The Richmond Agitation-Sedation Scale: Validity and reliability in adult intensive care unit patients. Am J Respir Crit Care Med 2002; 166: 1338-1344.
65. Setoguchi S, Stevenson LW, Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. Am Heart J 2007; 154: 260-266.
66. Tsuchihashi M, Tsutsui H, Kodama K, Kasagi F, Setoguchi S, Mohr M, et al. Medical and socioenvironmental predictors of hospital readmission in patients with congestive heart failure. Am Heart J 2001; 142: E7.
67. Koelling TM, Johnson ML, Cody RJ, Aaronson KD. Discharge education improves clinical outcomes in patients with chronic heart failure. Circulation 2005; 111: 179-185.
68. Paul S. Hospital discharge education for patients with heart failure: What really works and what is the evidence? Crit Care Nurse 2008; 28: 66-82.
69. Konick-McMahan J, Bixby B, Mckenna C. Heart failure in older adults. Providing nursing care to improve outcomes. J Gerontol Nurs 2003; 29: 35-41.
70. Guidelines for the Diagnosis and Treatment of Cardiovascular Diseases (2009 Joint Working Groups Report). Guidelines for Treatment of Chronic Heart Failure (JCS 2010). http://www.j-circ.or.jp/guideline/pdf/JCS2010_matsuzaki_h.pdf (in Japanese).
71. Kato N, Ito N, Kinugawa K, Kazuma K. Validity and reliability of the Japanese version of the European Heart Failure Self-Care Behavior Scale. Eur J Cardiovasc Nurs 2008; 7: 284-289.
72. Vaccarino V, Kasl SV, Abramson J, Krumholz HM. Depressive symptoms and risk of functional decline and death in patients with heart failure. J Am Coll Cardiol 2001; 38: 199-205.
73. Rozzini R, Sabatini T, Frisoni GB, Trabucchi M. Depression and major outcomes in older patients with heart failure. Arch Intern Med 2002; 162: 362-364.
74. Kato N, Kinugawa K, Yao A, Hatano M, Shiga T, Kazuma K. Relationship of depressive symptoms with hospitalization and death in Japanese patients with heart failure. J Card Fail 2009; 15: 912-919.
75. Tsuchihashi-Makaya M, Kato N, Chishaki A, Takeshita A, Tsutsui H. Anxiety and poor social support are independently associated with adverse outcomes in patients with mild heart failure. Circ J 2009; 73: 280-287.
76. Hutt E, Frederickson E, Ecord M, Kramer AM. Associations among processes and outcomes of care for Medicare nursing home residents with acute heart failure. J Am Med Dir Assoc 2003; 4: 195-199.
77. Pi-Figueras M, Aguilera A, Arellano M, Miralles R, Garcia-Caselles P, Torres R, et al. Prevalence of delirium in a geriatric convalescence hospitalization unit: Patient's clinical characteristics and risk precipitating factor analysis. Arch Gerontol Geriatr Suppl 2004; 333-337.
78. Ely EW, Shintani A, Truman B, Speroff T, Gordon SM, Harrell FE Jr, et al. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA 2004; 291: 1753-1762.
79. Inada K. The pathophysiology and causes. In: Nishimura K, Yamauchi N, editors. The best way to treat delirium: Techniques to avoid worsening. Japanese Journal of Nursing Techniques 2011; 57(Suppl): 9-16 (in Japanese).
80. Inouye SK, Bogardus ST Jr, Charpentier PA, Leo-Summers L, Acampora D, Holford TR, et al. A multicomponent intervention to prevent delirium in hospitalized older patients. N Engl J Med 1999; 340: 669-676.
81. Cole MG, McCusker J, Bellavance F, Primeau FJ, Bailey RF, Bonnycastle MJ, et al. Systematic detection and multidisciplinary care of delirium in older medical inpatients: A randomized trial. CMAJ 2002; 167: 753-759.
82. Machida I. Screening tools for delirium. Japanese Journal of General Hospital Psychiatry 2002; 14: 1-8 (in Japanese).
83. Neelon VJ, Champagne MT, Carlson JR, Funk SG. The NEECHAM Confusion Scale: Construction, validation, and clinical testing. Nurs Res 1996; 45: 324-330.
84. Ely EW, Margolin R, Francis J, May L, Truman B, Dittus R, et al. Evaluation of delirium in critically ill patients: Validation of the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). Crit Care Med 2001; 29: 1370-1379.
85. Japan Society of Respiratory Care Medicine. Guidelines for sedation during artifcial respiration. Japanese Journal of Respiratory Care 2007; 24: 146-167 (in Japanese).
86. Khan MG. Complications of myocardial infarction and postinfarction care. In: Khan MG, editor. Heart disease diagnosis and therapy: A practical approach, 2nd ed. New York: Human Press Inc., 2005; 69-107.
87. Grossman E, Messerli FH, Grodzicki T, Kowey P. Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? JAMA 1996; 276: 1328-1331.
88. Kajimoto K, Imai T, Minami Y, Kasanuki H. Comparison of acute reduction in left ventricular outfow tract pressure gradient in obstructive hypertrophic cardiomyopathy by disopyramide versus pil-sicainide versus cibenzoline. Am J Cardiol 2010; 106: 1307-1312.
89. Cooper LT Jr, Berry GJ, Shabetai R. Idiopathic giant-cell myocar-ditis--natural history and treatment. N Engl J Med 1997; 336: 1860-1866.
90. Ohuchida M, Imaizumi T. Treatment strategies for fulminant myocarditis: Steroid therapy. In: Izumi T, editor. Clinical practice for fulminant myocarditis. Tokyo: Igaku-Shoin Ltd., 2002; 71-80 (in Japanese).
91. Kodama M, Okura Y, Hirono S, Hanawa H, Ogawa Y, Itoh M, et al. A new scoring system to predict the effcacy of steroid therapy for patients with acute myocarditis--a retrospective study. Jpn Circ J 1998; 62: 715-720.
92. Kato S, Morimoto S, Hiramitsu S, Uemura A, Ohtsuki M, Kato Y, et al. Successful high-dose intravenous immunoglobulin therapy for a patient with fulminant myocarditis. Heart Vessels 2007; 22: 48-51.
93. Robinson JL, Hartling L, Crumley E, Vandermeer B, Klassen TP. A systematic review of intravenous gamma globulin for therapy of acute myocarditis. BMC Cardiovasc Disord 2005; 5: 12.
94. Guidelines for the Diagnosis and Treatment of Cardiovascular Diseases (2006 Joint Working Groups Report). Guidelines for Surgical and Interventional Treatment of Valvular Heart Disease (JCS 2007). http://www.j-circ.or.jp/guideline/pdf/JCS2007_matsuda_h.pdf (in Japanese).
95. Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr, Faxon DP, Freed MD, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2008; 52: e1-e142.
96. Sezai A, Hata M, Niino T, Yoshitake I, Unosawa S, Wakui S, et al. Infuence of continuous infusion of low-dose human atrial natriuretic peptide on renal function during cardiac surgery: A randomized controlled study. J Am Coll Cardiol 2009; 54: 1058-1064.
97. Morikawa S, Sone T, Tsuboi H, Mukawa H, Morishima I, Uesugi M, et al. Renal protective effects and the prevention of contrast-induced nephropathy by atrial natriuretic peptide. J Am Coll Cardiol 2009; 53: 1040-1046.
98. Nigwekar SU, Navaneethan SD, Parikh CR, Hix JK. Atrial natriuretic peptide for management of acute kidney injury: A systematic review and meta-analysis. Clin J Am Soc Nephrol 2009; 4: 261-272.
99. Russell SD, Rogers JG, Milano CA, Dyke DB, Pagani FD, Aranda JM, et al; HeartMate II Clinical Investigators. Renal and hepatic function improve in advanced heart failure patients during contin-uous-fow support with the HeartMate II left ventricular assist device. Circulation 2009; 120: 2352-2357.
100. The Japanese Respiratory Society. Writing Committee of the Guidelines for the Management of Hospital-Acquired Pneumonia in Adults. The JRS Guidelines for the Management of Hospital-Acquired Pneumonia in Adults. Tokyo: The Japanese Respiratory Society, 2008 (in Japanese).
101. Shinbane JS, Wood MA, Jensen DN, Ellenbogen KA, Fitzpatrick AP, Scheinman MM. Tachycardiainduced cardiomyopathy: A review of animal models and clinical studies. J Am Coll Cardiol 1997; 29: 709-715.
102. Van Gelder IC, Crijns HJ, Blanksma PK, Landsman ML, Posma JL, Van Den Berg MP, et al. Time course of hemodynamic changes and improvement of exercise tolerance after cardioversion of chronic atrial fbrillation unassociated with cardiac valve disease. Am J Cardiol 1993; 72: 560-566.
103. Umana E, Solares CA, Alpert MA. Tachycardia-induced cardiomyopathy. Am J Med 2003; 114: 51-55.
104. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, et al; Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fbrillation. N Engl J Med 2002; 347: 1825-1833.
105. Hsu LF, Jaïs P, Sanders P, Garrigue S, Hocini M, Sacher F, et al. Catheter ablation for atrial fbrillation in congestive heart failure. N Engl J Med 2004; 351: 2373-2383.
106. Le Jemtel TH, Padeletti M, Jelic S. Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol 2007; 49: 171-180.
107. Sin DD, Man SF. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc 2005; 2: 8-11.
108. Rutten FH, Cramer MJ, Grobbee DE, Sachs AP, Kirkels JH, Lammers JW, et al. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J 2005; 26: 1887-1894.
109. Shelton RJ, Rigby AS, Cleland JG, Clark AL. Effect of a community heart failure clinic on uptake of beta blockers by patients with obstructive airways disease and heart failure. Heart 2006; 92: 331-336.
110. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, et al; UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543-1554.
111. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al; TORCH investigators. Salmeterol and futicasone pro-pionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789.
112. Tsuchihashi-Makaya M, Hamaguchi S, Kinugawa S, Yokota T, Goto D, Yokoshiki H, et al; JCARE-CARD Investigators. Characteristics and outcomes of hospitalized patients with heart failure and reduced vs preserved ejection fraction: Report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 2009; 73: 1893-1900.
113. Miyagishima K, Hiramitsu S, Kimura H, Mori K, Ueda T, Kato S, et al. Long term prognosis of chronic heart failure: Reduced vs preserved left ventricular ejection fraction. Circ J 2009; 73: 92-99.
114. Yamamoto K, Sakata Y, Ohtani T, Takeda Y, Mano T. Heart failure with preserved ejection fraction. Circ J 2009; 73: 404-410.
115. Gandhi SK, Powers JC, Nomeir AM, Fowle K, Kitzman DW, Rankin KM, et al. The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med 2001; 344: 17-22.
116. Nishio M, Sakata Y, Mano T, Ohtani T, Takeda Y, Hori M, et al. Difference of clinical characteristics between hypertensive patients with and without diastolic heart failure: The roles of diastolic dysfunction and renal insuffciency. Hypertens Res 2008; 31: 1865-1872.
117. Kawaguchi M, Hay I, Fetics B, Kass DA. Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: Implications for systolic and diastolic reserve limitations. Circulation 2003; 107: 714-720.
118. Penicka M, Bartunek J, Trakalova H, Hrabakova H, Maruskova M, Karasek J, et al. Heart failure with preserved ejection fraction in outpatients with unexplained dyspnea: A pressure-volume loop analysis. J Am Coll Cardiol 2010; 55: 1701-1710.
119. Yamaguchi H, Yoshida J, Yamamoto K, Sakata Y, Mano T, Akehi N, et al. Elevation of plasma brain natriuretic peptide is a hallmark of diastolic heart failure independent of ventricular hypertrophy. J Am Coll Cardiol 2004; 43: 55-60.
120. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial. Lancet 2003; 362: 777-781.
121. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J; PEP-CHF Investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006; 27: 2338-2345.
122. van Veldhuisen DJ, Cohen-Solal A, Böhm M, Anker SD, Babalis D, Roughton M, et al; SENIORS Investigators. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospital-ization in Seniors With Heart Failure). J Am Coll Cardiol 2009; 53: 2150-2158.
123. Costanzo MR, Saltzberg MT, Jessup M, Teerlink JR, Sobotka PA; Ultrafltration Versus Intravenous Diuretics for Patients Hospitalized for Acute Decompensated Heart Failure (UNLOAD) Investigators. Ultrafltration is associated with fewer rehospitalizations than continuous diuretic infusion in patients with decompensated heart failure: results from UNLOAD. J Card Fail 2010; 16: 277-284.
124. Costanzo MR. Ultrafltration in the management of heart failure. Curr Opin Crit Care 2008; 14: 524-530.
125. Jaski BE, Fifer MA, Wright RF, Braunwald E, Colucci WS. Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside. J Clin Invest 1985; 75: 643-649.
126. Campana C, Pasotti M, Monti L, Revera M, Serio A, Nespoli L, et al. The evaluation of right ventricular performance in different clinical models of heart failure. Eur Heart J Suppl 2004; 6: F61-F67.
127. Voelkel NF, Quaife RA, Leinwand LA, Barst RJ, McGoon MD, Meldrum DR, et al; National Heart, Lung, and Blood Institute Working Group on Cellular and Molecular Mechanisms of Right Heart Failure. Right ventricular function and failure: Report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation 2006; 114: 1883-1891.
128. Guidelines for the Diagnosis and Treatment of Cardiovascular Diseases (2005 Joint Working Groups Report). Guidelines for Treatment of Pulmonary Hypertension (JCS 2006). http://www.j-circ.or.jp/guideline/pdf/JCS2006_nakano_h.pdf (in Japanese).
129. Yoshikawa T, Baba A, Suzuki M, Yokozuka H, Okada Y, Nagami K, et al. Effectiveness of carvedilol alone versus carvedilol + pimobendan for severe congestive heart failure. For the Keio Interhospital Cardiology Study (KICS) Group. Am J Cardiol 2000; 85: 1495-1497; A7.
130. Stevenson LW, Massie BM, Francis GS. Optimizing therapy for complex or refractory heart failure: A management algorithm. Am Heart J 1998; 135(6 Pt 2 Su): S293-S309.
131. Gheorghiade M, Pang PS. Acute heart failure syndromes. J Am Coll Cardiol 2009; 53: 557-573.
132. Ozawa T. Care for end-stage patients. In: Izumi T, Tsutsui H, editors. Treatment strategies for prevention of occurrence and recurrence of heart failure. Tokyo: Nakayama Shoten Co. Ltd., 2006; 343-350 (in Japanese).
133. Guidelines for the Diagnosis and Treatment of Cardiovascular Diseases (2008-2009 Joint Working Groups Report). Statement for end-stage cardiovascular care (JCS 2010). http://www.j-circ.or.jp/ guideline/pdf/JCS2010_nonogi_h.pdf (in Japanese).
134. Murata H. Spiritual pain and its care in patients with end-stage cancer: Development of conceptual framework for assessment and care. Japanese Journal of Palliative Medicine 2003; 5: 157-165 (in Japanese).
135. Ozawa T. Theoretical approach for spiritual pain and its care. Rinsho Kango 2004; 30: 1076-1086 (in Japanese).